All News

Hawken Miller is a journalist, bringing his experience writing for outlets like The Washington Post and BioNews, along with his personal experience living with Duchenne muscular dystrophy, to CureDuchenne. Learn more about Hawken here.

Edgewise Therapeutics, which received early funding from CureDuchenne, announced positive 6-month interim results from the ongoing ARCH study, an open label study of EDG-5506 in adults with Becker muscular dystrophy. Edgewise […]